{"id":"glucagon","rwe":[{"pmid":"41905933","year":"2026","title":"Effects of plant flavonoids and selenium on pancreatic hormones and glucose homeostasis in autoimmune thyroiditis.","finding":"","journal":"Experimental animals","studyType":"Clinical Study"},{"pmid":"41905685","year":"2026","title":"A cross-sectional study of prescribing rates for SGLT2 inhibitors and GLP-1 receptor agonists among primary care clinics with and without embedded pharmacists.","finding":"","journal":"Journal of the American Pharmacists Association : JAPhA","studyType":"Clinical Study"},{"pmid":"41905619","year":"2026","title":"Obesity Management in End-Stage Kidney Disease: Pathways to Improve Kidney Transplant Access.","finding":"","journal":"American journal of kidney diseases : the official journal of the National Kidney Foundation","studyType":"Clinical Study"},{"pmid":"41905447","year":"2026","title":"Genetic Variations in GLP-1R: Impact on Diabetes and Obesity Therapeutics.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"41904760","year":"2026","title":"Tirzepatide mitigates atherosclerosis progression and modulates oxLDL-mediated proatherogenic effects in macrophages: evidence for M1/M2 homeostasis restoration.","finding":"","journal":"Archives of pharmacal research","studyType":"Clinical Study"}],"_fda":{"id":"e1d65360-2785-4308-8a64-5c2c9e812868","risks":["Risk Summary Available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation. In a rat reproduction study, no embryofetal toxicity was observed with glucagon administered by injection during the period of organogenesis at doses representing up to 40 times the human dose, based on body surface area (mg/m 2 ) (see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.","Risk Summary There is no information available on the presence of glucagon in human or animal milk, the effects of glucagon on the breastfed child or the effects of glucagon on milk production. However, glucagon is a peptide and would be expected to be broken down to its constituent amino acids in the infant's digestive tract and is therefore, unlikely to cause harm to an exposed infant."],"set_id":"15b49500-0aae-4e25-9a1d-709983233cc6","openfda":{"rxcui":["310497"],"spl_id":["e1d65360-2785-4308-8a64-5c2c9e812868"],"brand_name":["Glucagon"],"spl_set_id":["15b49500-0aae-4e25-9a1d-709983233cc6"],"package_ndc":["0378-8067-90","0378-8065-32","0378-8066-32"],"product_ndc":["0378-8067"],"generic_name":["GLUCAGON"],"product_type":["HUMAN PRESCRIPTION DRUG"],"manufacturer_name":["Mylan Pharmaceuticals Inc."],"application_number":["ANDA204468"],"is_original_packager":[true]},"version":"2","pregnancy":["8.1 Pregnancy Risk Summary Available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation. In a rat reproduction study, no embryofetal toxicity was observed with glucagon administered by injection during the period of organogenesis at doses representing up to 40 times the human dose, based on body surface area (mg/m 2 ) (see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In pregnant rats given animal sourced glucagon twice-daily by injection at doses up to 2 mg/kg (up to 40 times the human dose based on body surface area extrapolation, mg/m 2 ) during the period of organogenesis, there was no evidence of increased malformations or embryofetal lethality."],"overdosage":["10 OVERDOSAGE If overdosage occurs, the patient may experience nausea, vomiting, inhibition of GI tract motility, increase in blood pressure and pulse rate. In case of suspected overdosing, the serum potassium may decrease and should be monitored and corrected if needed. If the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed."],"description":["11 DESCRIPTION Glucagon is an antihypoglycemic agent and a gastrointestinal motility inhibitor. Glucagon is produced by solid state peptide synthesis. The chemical structure of the glucagon is identical to human glucagon. Glucagon is a single-chain polypeptide that contains 29 amino acid residues and has a molecular weight of 3482.8 Daltons. The empirical formula is C 153 H 225 N 43 O 49 S. The primary sequence of glucagon is shown below. Glucagon (synthetic origin) is a white to off-white powder. It is relatively insoluble in water but is soluble at a pH of less than 3 or more than 9.5. Glucagon for injection, USP is a sterile, white to off white lyophilized powder or plug in a vial and a syringe of sterile diluent for intravenous, intramuscular, or subcutaneous use. The vial contains 1 mg of glucagon USP, 49 mg of lactose monohydrate. Hydrochloric acid may have been added during manufacture to adjust the pH of the glucagon to 2.5 to 3.0. One International Unit of glucagon is equivalent to 1 mg of glucagon. The 1 mL diluent syringe contains 12 mg of glycerin, 1 mg hydrochloric acid, and Water for Injection, at pH 1.8 to 2.2. Glucagon Primary Sequence"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Glucagon Emergency Kit for Low Blood Sugar contains 1 mg Glucagon for Injection, USP (a sterile, lyophilized white to off-white powder or plug) in a single-dose vial and 1 prefilled syringe containing 1 mL of diluent of Glucagon. • 1 mg per vial - with 1 mL of diluting solution (PFS) (1s) NDC of Pre-filled Syringe: 0378-8066-32; NDC of Vial Label: 0378-8065-32; NDC of Carton: 0378-8067-90. 16.2 Storage and Handling Before Reconstitution: Store Glucagon for Injection, USP at controlled room temperature 20° to 25°C (68° to 77°F) [See USP]. Do not use Glucagon for Injection, USP if the expiration date has passed. Do not freeze. Keep in its original package and away from light. After Reconstitution: Use reconstituted Glucagon for Injection, USP immediately. Discard unused portion [see Dosage and Administration (2.3) ]."],"geriatric_use":["8.5 Geriatric Use Clinical studies of glucagon did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient when used as a diagnostic aid should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Glucagon for Injection for the treatment of severe hypoglycemia in pediatric patients with diabetes have been established. Safety and effectiveness for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in pediatric patients have not been established."],"effective_time":"20241215","pharmacodynamics":["12.2 Pharmacodynamics Treatment of Severe Hypoglycemia Blood glucose concentrations rise within 10 minutes of subcutaneous injection and mean maximal concentration of 136 mg/dL is attained 30 minutes after injection (see Figure 1). Similarly, following intramuscular injection, the mean peak glucose level was 138 mg/dL, which occurred at 26 minutes after injection. Figure 1 Mean (SE) blood glucose concentrations after subcutaneous injection of glucagon (1 mg) in 25 normal volunteers Figure 1 Mean (SE) blood glucose concentrations after subcutaneous injection of glucagon (1 mg) in 25 normal volunteers Diagnostic Aid Table 2 displays the dose and pharmacodynamics properties of Glucagon for Injection as a diagnostic aid during radiological examination. Table 2: Dose and Pharmacodynamic properties of Glucagon for Injection as a Diagnostic Aid Dose Route of administration Time of onset of action Approximate duration of effect 0.25 to 0.5 mg Intravenous 1 minute 9 to 17 minutes 1 mg Intramuscular 8 to 10 minutes 12 to 27 minutes 2 mg *Administration of 2 mg doses produces a higher incidence of nausea and vomiting than do lower doses. Intravenous 1 minute 22 to 25 minutes 2 mg Intramuscular 4 to 7 minutes 21 to 32 minutes"],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Glucagon injected through the intramuscular route achieved mean peak plasma levels of 6.9 ng/mL at approximately 13 minutes after dosing; and 7.9 ng/mL at approximately 20 minutes after subcutaneous dosing. Administration of the intravenous glucagon showed dose proportionality of the pharmacokinetics between 0.25 and 2 mg. Figure 2 Mean (SE) serum glucagon concentrations after subcutaneous injection of glucagon (1 mg) in 25 normal volunteers Figure 2 Mean (SE) serum glucagon concentrations after subcutaneous injection of glucagon (1 mg) in 25 normal volunteers Distribution The mean volume of distribution was 0.25 L/kg. Elimination The mean clearance was 13.5 mL/min/kg. The mean half-life ranged from 8 to 18 minutes. Metabolism Glucagon is degraded in the liver, kidney and plasma."],"adverse_reactions":["6 ADVERSE REACTIONS The following important adverse reactions are described below and elsewhere in the labeling: • Hypersensitivity and Allergic Reactions [see Warnings and Precautions (5.3) ] • Necrolytic Migratory Erythema [see Warnings and Precautions (5.5) ] • Hyperglycemia in Patients with Diabetes Mellitus when Used as a Diagnostic Aid [see Warnings and Precautions (5.6) ] • Blood Pressure and Heart Rate Increase in Patients with Cardiac Disease when used as a Diagnostic Aid [see Warnings and Precautions (5.7) ] The following adverse reactions have been identified during post-approval use of glucagon. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. • Injection site reactions including erythema and swelling • Nausea • Vomiting • Headache • Dizziness • Asthenia • Pallor • Diarrhea • Somnolence • Generalized allergic reactions including anaphylactic shock with breathing difficulties and hypotension • Hypertension and tachycardia • Decreased blood pressure. Hypotension has been reported up to 2 hours after administration in patients receiving glucagon as premedication for upper gastrointestinal endoscopy procedures. • Hypoglycemia and hypoglycemic coma. Patients taking indomethacin may be more likely to experience hypoglycemia following glucagon administration [see Drug Interactions (7) ] . • Necrolytic Migratory Erythema (NME) cases have been reported post marketing in patients receiving continuous infusion of glucagon. Glucagon adverse reactions include: injection site reactions, nausea, vomiting, headache, dizziness, asthenia, pallor, diarrhea, somnolence, and decreased blood pressure. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["4 CONTRAINDICATIONS Glucagon for Injection is contraindicated in patients with: • Pheochromocytoma because of the risk of substantial increase in blood pressure [see Warning and Precautions (5.1) ] • Insulinoma because of the risk of hypoglycemia [see Warning and Precautions (5.2) ] • Known hypersensitivity to glucagon or any of the excipients in Glucagon for Injection. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension [see Warning and Precautions (5.3) ] • Glucagonoma when used as a diagnostic aid because of the risk of hypoglycemia [see Warnings and Precautions (5.8) ] • Pheochromocytoma ( 4 ) • Insulinoma ( 4 ) • Known hypersensitivity to glucagon or to any of the excipients ( 4 ) • Glucagonoma when used as a diagnostic aid ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Table 1: Clinically Significant Drug Interactions with Glucagon for Injection Beta-Blockers Clinical Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given Glucagon for Injection. Intervention: The increase in blood pressure and heart rate may require therapy in patients with coronary artery disease. Indomethacin Clinical Impact: In patients taking indomethacin, Glucagon for Injection may lose its ability to raise blood glucose or may even produce hypoglycemia. Intervention: Monitor blood glucose levels during glucagon treatment of patients taking indomethacin. Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs and Glucagon for Injection increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. Intervention: Concomitant use of anticholinergic drugs with Glucagon for Injection for use as a diagnostic aid is not recommended. Warfarin Clinical Impact: Glucagon for Injection may increase the anticoagulant effect of warfarin. Intervention: Monitor patients for unusual bruising or bleeding, as adjustments in warfarin dosage may be required. Insulin Clinical Impact: Insulin acts antagonistically to glucagon. Intervention: Monitor blood glucose when Glucagon for Injection is used as a diagnostic aid in patients receiving insulin. • Beta-blockers : Patients taking beta-blockers may have a transient increase in pulse and blood pressure. ( 7 ) • Indomethacin : In patients taking indomethacin Glucagon for Injection may lose its ability to raise glucose or may produce hypoglycemia. ( 7 ) • Anticholinergic drugs : Concomitant use of anticholinergic drugs with Glucagon for Injection for use as a diagnostic aid is not recommended. ( 7 ) • Warfarin : Glucagon for Injection may increase the anticoagulant effect of warfarin. ( 7 ) • Insulin : Monitor blood glucose when Glucagon for Injection is used as a diagnostic aid in patients receiving insulin. ( 7 )"],"mechanism_of_action":["12.1 Mechanism of Action Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon."],"instructions_for_use":["INSTRUCTIONS FOR USE Glucagon (GLOO-ka-gon) for Injection, USP Important • Read and become familiar with this Instructions for Use before an emergency happens. • Show your family members and others where you keep your Glucagon Emergency Kit for Low Blood Sugar and how to use it the right way. • Call for emergency medical help right after you use Glucagon for Injection. • Do not share your Glucagon syringes or needles with another person. You may give other people a serious infection or get a serious infection from them. • The prefilled syringe that comes with your Glucagon Emergency Kit for Low Blood Sugar is for use with Glucagon for Injection only. Do not use Glucagon for Injection syringes to inject other medicines. How should I store Glucagon for Injection? Before you mix the Glucagon powder and liquid: • Store Glucagon at room temperature between 68° to 77°F (20° to 25°C). • Check the expiration date on the vial of Glucagon for Injection. Do not use Glucagon for Injection if the expiration date has passed. • Do not freeze Glucagon. • Keep Glucagon in its original package and away from light. After you mix the Glucagon powder and liquid: • Use Glucagon for Injection right away. • Throw away unused Glucagon for Injection. Supplies you will need for your Glucagon for Injection • Glucagon Emergency Kit for Low Blood Sugar contains (see Figure A): • 1 single-dose vial containing 1 mg Glucagon for Injection (as a sterile, white to off-white lyophilized powder or plug) • 1 prefilled syringe containing 1 mL of diluent for Glucagon Figure A • 1 puncture resistant container for throwing away used needles and syringes. See “How should I dispose of (throw away) used Glucagon syringes?” at the end of these instructions. • Alcohol swab (not included in kit) Preparing to Inject Glucagon for Injection • The Glucagon medicine comes as a dry powder. Before you use Glucagon for Injection, you must mix the dry powder with the syringe of diluent that comes in the Glucagon Emergency Kit for Low Blood Sugar. Do not use any other liquid to mix the medicine. Step 1: Remove the flip-off seal from the vial of Glucagon. Wipe the rubber stopper on the vial with an alcohol swab (see Figure B). Figure B Step 2: Remove the needle protector from the syringe. Inject all of the diluent in the prefilled syringe into the vial containing Glucagon powder (see Figure C). Do not remove the plastic clip from the syringe. Remove syringe from the vial. Figure C Step 3: Swirl the vial gently until the Glucagon powder dissolves completely (see Figure D). Glucagon should not be used unless the solution is clear and of a water-like consistency. Figure D Step 4: Using the same syringe, hold the vial upside down and, making sure the needle tip remains in the solution, gently withdraw all the solution (1 mg mark on syringe) from the vial (see Figure E). The backstop and plastic clip on the syringe will prevent the rubber stopper from being pulled out of the syringe; however, if the plunger rod separates from the rubber stopper, simply reinsert the rod by turning it clockwise. The usual adult dose is 1 mg. For children weighing less than 44 lb (20 kg), give 1/2 adult dose (0.5 mg). For these children, withdraw 1/2 of the solution from the vial (0.5 mg mark on syringe). Figure E Injecting Glucagon for Injection Step 5: Choose your injection site and clean with an alcohol wipe. Injection sites for Glucagon for Injection are the buttocks, upper arm, or thigh. Step 6: Insert the needle into the loose tissue under the clean injection site and push the plunger to inject all (or 1/2 for children weighing less than 44 lbs.) of the Glucagon for Injection. After injecting Glucagon for Injection Step 7: Apply light pressure at the injection site and withdraw the needle. Press an alcohol swab against the injection site. Throw away your used syringe with the needle attached and any Glucagon that you did not use in an FDA-cleared sharps disposal container right away after use. See “How should I dispose of (throw away) used Glucagon syringes?” at the end of these instructions. Step 8: Turn the person on their side. When an unconscious person wakes up, they may vomit. Turning the person on their side will prevent them from choking. Step 9: Call for emergency medical help right away. Step 10 : Feed the person as soon as they wake up and are able to swallow . Give the person a fast-acting source of sugar (such as a regular soft drink or fruit juice) and a long-acting source of sugar (such as crackers and cheese or a meat sandwich). Step 11: If the person does not awaken within 15 minutes, give another dose of Glucagon and inform a doctor or emergency services right away . Step 12: Even if the Glucagon revives the person, their doctor should be notified right away. A doctor should be notified whenever severe hypoglycemia occurs. Hypoglycemia may happen again after receiving Glucagon for Injection. Early symptoms of hypoglycemia (low blood glucose) include: • sweating • drowsiness • dizziness • sleep disturbances • irregular heartbeat • anxiety • tremor • blurred vision • hunger • slurred speech • restlessness • depressed mood • tingling in the hands, feet, lips or tongue. • irritability • abnormal behavior • lightheadedness • unsteady movement • inability to concentrate • personality change • headache If not treated early, the symptoms may progress to severe hypoglycemia. Signs include: • confusion • unconsciousness • seizures • death How should I dispose of (throw away) used Glucagon syringes? • Put used syringes in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash. • If you do not have an FDA-cleared sharps disposal container, you may use a household container that is: • made of a heavy-duty plastic, • can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, • upright and stable during use, • leak-resistant, and • properly labelled to warn of hazardous waste inside the container. • When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal . • Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container. Keep Glucagon for Injection and all medicines out of the reach of children. This Instructions for Use has been approved by the U.S. Food and Drug Administration. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A Manufactured by: Mylan Laboratories Limited Bangalore, India DECEMBER 2024 Figure A Figure B Figure C Figure D Figure E"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon. 12.2 Pharmacodynamics Treatment of Severe Hypoglycemia Blood glucose concentrations rise within 10 minutes of subcutaneous injection and mean maximal concentration of 136 mg/dL is attained 30 minutes after injection (see Figure 1). Similarly, following intramuscular injection, the mean peak glucose level was 138 mg/dL, which occurred at 26 minutes after injection. Figure 1 Mean (SE) blood glucose concentrations after subcutaneous injection of glucagon (1 mg) in 25 normal volunteers Figure 1 Mean (SE) blood glucose concentrations after subcutaneous injection of glucagon (1 mg) in 25 normal volunteers Diagnostic Aid Table 2 displays the dose and pharmacodynamics properties of Glucagon for Injection as a diagnostic aid during radiological examination. Table 2: Dose and Pharmacodynamic properties of Glucagon for Injection as a Diagnostic Aid Dose Route of administration Time of onset of action Approximate duration of effect 0.25 to 0.5 mg Intravenous 1 minute 9 to 17 minutes 1 mg Intramuscular 8 to 10 minutes 12 to 27 minutes 2 mg *Administration of 2 mg doses produces a higher incidence of nausea and vomiting than do lower doses. Intravenous 1 minute 22 to 25 minutes 2 mg Intramuscular 4 to 7 minutes 21 to 32 minutes 12.3 Pharmacokinetics Absorption Glucagon injected through the intramuscular route achieved mean peak plasma levels of 6.9 ng/mL at approximately 13 minutes after dosing; and 7.9 ng/mL at approximately 20 minutes after subcutaneous dosing. Administration of the intravenous glucagon showed dose proportionality of the pharmacokinetics between 0.25 and 2 mg. Figure 2 Mean (SE) serum glucagon concentrations after subcutaneous injection of glucagon (1 mg) in 25 normal volunteers Figure 2 Mean (SE) serum glucagon concentrations after subcutaneous injection of glucagon (1 mg) in 25 normal volunteers Distribution The mean volume of distribution was 0.25 L/kg. Elimination The mean clearance was 13.5 mL/min/kg. The mean half-life ranged from 8 to 18 minutes. Metabolism Glucagon is degraded in the liver, kidney and plasma."],"indications_and_usage":["1 INDICATIONS AND USAGE Glucagon for Injection is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated: • for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes. ( 1.1 ) • as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. ( 1.2 ) 1.1 Severe Hypoglycemia Glucagon for Injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. 1.2 Diagnostic Aid Glucagon for Injection is indicated as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Substantial Increase in Blood Pressure in Patients with Pheochromocytoma : Contraindicated in patients with pheochromocytoma because Glucagon for Injection may stimulate the release of catecholamines from the tumor. ( 4 , 5.1 ) • Hypoglycemia in Patients with Insulinoma : In patients with insulinoma, glucagon administration may produce an initial increase in blood glucose; however, Glucagon for Injection may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. If a patient develops symptoms of hypoglycemia after a dose of Glucagon for Injection, give glucose orally or intravenously. ( 4 , 5.2 ) • Hypersensitivity and Allergic Reactions : Allergic reactions, which have been reported with glucagon, may occur and include generalized rash, and in some cases anaphylactic shock with breathing difficulties, and hypotension. ( 4 , 5.3 ) • Lack of Efficacy in Patients with Decreased Glycogen: Glucagon for Injection is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for Glucagon for Injection administration to be effective. Patients with these conditions should be treated with glucose. ( 5.4 ) • Necrolytic Migratory Erythema (NME): Necrolytic migratory erythema (NME), a skin rash, have been reported post marketing following continuous glucagon infusion and resolved with discontinuation of the glucagon. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks. ( 5.5 ) • Hyperglycemia in Patients with Diabetes Mellitus when Used as a Diagnostic Aid : Treatment with Glucagon for Injection in patients with diabetes mellitus may cause hyperglycemia. Monitor diabetic patients for changes in blood glucose levels during treatment and treat if indicated. ( 5.6 ) • Blood Pressure and Heart Rate Increase in Patients with Cardiac Disease when Used as a Diagnostic Aid : Glucagon for Injection may increase myocardial oxygen demand, blood pressure, and pulse rate. Cardiac monitoring is recommended in patients with cardiac disease during use of Glucagon for Injection as a diagnostic aid, and an increase in blood pressure and pulse rate may require therapy. ( 5.7 ) • Hypoglycemia in Patients with Glucagonoma: Glucagon administered to patients with glucagonoma may cause secondary hypoglycemia. Test patients suspected of having glucagonoma for blood levels of glucagon prior to treatment. ( 4 , 5.8 ) 5.1 Substantial Increase in Blood Pressure in Patients with Pheochromocytoma Glucagon for Injection is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor [see Contraindications (4) ]. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure. 5.2 Hypoglycemia in Patients with Insulinoma In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, Glucagon for Injection administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. Glucagon for Injection is contraindicated in patients with insulinoma [see Contraindications (4) ]. If a patient develops symptoms of hypoglycemia after a dose of Glucagon for Injection, give glucose orally or intravenously. 5.3 Hypersensitivity and Allergic Reactions Allergic reactions have been reported with glucagon, these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. Glucagon for Injection is contraindicated in patients with a prior hypersensitivity reaction [see Contraindications (4) ] . 5.4 Lack of Efficacy in Patients with Decreased Hepatic Glycogen Glucagon for Injection is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for Glucagon for Injection administration to be effective. Patients with these conditions should be treated with glucose. 5.5 Necrolytic Migratory Erythema Necrolytic Migratory Erythema (NME), a skin rash commonly associated with glucagonomas (glucagon-producing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported post marketing following continuous glucagon infusion. NME lesions may affect the face, groin, perineum and legs or be more widespread. In the reported cases, NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks. 5.6 Hyperglycemia in Patients with Diabetes Mellitus when Used as a Diagnostic Aid Treatment with Glucagon for Injection in patients with diabetes mellitus may cause hyperglycemia. Monitor diabetic patients for changes in blood glucose levels during treatment and treat if indicated. 5.7 Blood Pressure and Heart Rate Increase in Patients with Cardiac Disease when Used as a Diagnostic Aid Glucagon for Injection may increase myocardial oxygen demand, blood pressure, and pulse rate which may be life-threatening in patients with cardiac disease. Cardiac monitoring is recommended in patients with cardiac disease during use of Glucagon for Injection as a diagnostic aid, and an increase in blood pressure and pulse rate may require therapy. 5.8 Hypoglycemia in Patients with Glucagonoma Glucagon administered to patients with glucagonoma may cause secondary hypoglycemia. Test patients suspected of having glucagonoma for blood levels of glucagon prior to use as a diagnostic aid as Glucagon for Injection is contraindicated in this setting [see Contraindications (4) ]."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long term studies in animals to evaluate carcinogenic potential have not been performed. Recombinant glucagon was positive in the bacterial Ames assay. It was determined that an increase in colony counts was related to technical difficulties in running this assay with peptides. Studies in rats have shown that glucagon does not cause impaired fertility."],"pharmacodynamics_table":["<table styleCode=\"Noautorules\" width=\"100%\"><caption>Table 2: Dose and Pharmacodynamic properties of Glucagon for Injection as a Diagnostic Aid</caption><col width=\"24%\"/><col width=\"25%\"/><col width=\"24%\"/><col width=\"28%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dose</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Route of  administration</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Time of onset of  action</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Approximate duration of effect</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.25 to 0.5 mg</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Intravenous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1 minute</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9 to 17 minutes</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1 mg</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Intramuscular</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8 to 10 minutes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12 to 27 minutes</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2 mg<footnote ID=\"_Ref218665811\">*Administration of 2 mg doses produces a higher incidence of nausea and vomiting than do lower doses.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Intravenous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1 minute</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>22 to 25 minutes</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>2 mg<footnoteRef IDREF=\"_Ref218665811\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Intramuscular</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>4 to 7 minutes</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>21 to 32 minutes</paragraph></td></tr></tbody></table>"],"drug_interactions_table":["<table styleCode=\"Noautorules\" width=\"100%\"><caption>Table 1: Clinically Significant Drug Interactions with Glucagon for Injection</caption><col width=\"21%\"/><col width=\"79%\"/><tbody><tr><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Beta-Blockers</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">Clinical Impact:</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given Glucagon for Injection.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">Intervention:</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>The increase in blood pressure and heart rate may require therapy in patients with coronary artery disease.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Indomethacin</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">Clinical Impact:</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>In patients taking indomethacin, Glucagon for Injection may lose its ability to raise blood glucose or may even produce hypoglycemia.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">Intervention:</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Monitor blood glucose levels during glucagon treatment of patients taking indomethacin.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Anticholinergic Drugs</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">Clinical Impact:</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>The concomitant use of anticholinergic drugs and Glucagon for Injection increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">Intervention:</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Concomitant use of anticholinergic drugs with Glucagon for Injection for use as a diagnostic aid is not recommended.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Warfarin</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">Clinical Impact:</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Glucagon for Injection may increase the anticoagulant effect of warfarin.</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">Intervention:</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Monitor patients for unusual bruising or bleeding, as adjustments in warfarin dosage may be required.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Insulin</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">Clinical Impact:</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Insulin acts antagonistically to glucagon.</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"italics\">Intervention:</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Monitor blood glucose when Glucagon for Injection is used as a diagnostic aid in patients receiving insulin. </paragraph></td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Recognition of Severe Hypoglycemia Inform patient and family members or caregivers on how to recognize the signs and symptoms of severe hypoglycemia and the risks of prolonged hypoglycemia. Administration Review the Patient Information and Instructions for Use with the patient and family members or caregivers. Serious Hypersensitivity Inform patients that allergic reactions can occur with Glucagon for Injection. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions [see Warnings and Precautions (5.3) ]. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A Manufactured by: Mylan Laboratories Limited Bangalore, India DECEMBER 2024"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Dosage in adult and pediatric patients to treat severe hypoglycemia ( 2.2 ) • Adults and Pediatric Patients Weighing 20 kg or More: ▪ The recommended dosage is 1 mg (1 mL) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously. ▪ If there has been no response after 15 minutes, an additional 1 mg dose (1 mL) may be administered while waiting for emergency assistance. • Pediatric Patients Weighing Less Than 20 kg: ▪ The recommended dosage is 0.5 mg (0.5 mL) or dose equivalent to 20 mcg/kg to 30 mcg/kg injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously. ▪ If there has been no response after 15 minutes, an additional 0.5 mg dose (0.5 mL) may be administered while waiting for emergency assistance. Important Administration Instructions for Using Glucagon for Injection to Treat Severe Hypoglycemia ( 2.1 ) • Glucagon for Injection is for subcutaneous, intramuscular, or intravenous injection. Administer intravenously ONLY under medical supervision. • See the Full Prescribing Information for administration instructions Dosage in Adults for Using Glucagon for Injection as a Diagnostic Aid ( 2.4 ) • Doses required for relaxation of the stomach, duodenum, and small bowel, depend on the onset and duration of effect required for the examination. • The dose for relaxation of the duodenum and small bowel is 0.25 mg to 0.5 mg given intravenously or 1 mg given intramuscularly. • For the stomach 0.5 mg intravenous or 2 mg intramuscular doses are recommended. • For the colon, it is recommended that a 2 mg dose be administered intramuscularly approximately 10 minutes prior to the procedure. • See the Full Prescribing Information for administration instructions ( 2.3 ) 2.1 Important Administration Instructions for Using Glucagon for Injection to Treat Severe Hypoglycemia Glucagon for Injection is for subcutaneous, intramuscular, or intravenous injection. Administer intravenously ONLY under medical supervision. Instruct patients and their caregivers on the signs and symptoms of severe hypoglycemia. Because severe hypoglycemia requires the help of others to recover, instruct the patient to inform those around them about Glucagon for Injection and its Instructions for Use. Administer Glucagon for Injection as soon as possible when severe hypoglycemia is recognized. Instruct the patient or caregiver to read the Instructions for Use at the time they receive a prescription for Glucagon for Injection. Emphasize the following instructions to the patient or caregiver: • Using the supplied prefilled syringe, carefully insert the needle through the rubber stopper of the vial containing Glucagon for Injection powder and inject all the liquid from the syringe into the vial. • Swirl the vial gently until the powder is completely dissolved and no particles remain in the fluid. The reconstituted solution should be clear and of a water-like consistency at time of use. Inspect visually for particulate matter and discoloration. If the resulting solution is cloudy or contains particulate matter do not use. • The reconstituted solution is 1 mg per mL glucagon. Use immediately after reconstitution. • Immediately after reconstitution, use the same syringe to withdraw the correct dose of Glucagon for Injection. • Inject the solution subcutaneously or intramuscularly in the upper arm, thigh, or buttocks. In addition, healthcare providers may administer intravenously. • Call for emergency assistance immediately after administering the dose. • If there has been no response after 15 minutes, an additional dose of Glucagon for Injection may be administered while waiting for emergency assistance. • When the patient has responded to the treatment and is able to swallow, give oral carbohydrates to restore the liver glycogen and prevent recurrence of hypoglycemia. • Discard any unused portion. 2.2 Dosage for Treatment of Severe Hypoglycemia Adults and Pediatric Patients Weighing 20 kg or More • The recommended dosage is 1 mg (1 mL) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks. Alternatively, healthcare providers may administer the dose intravenously. • If there has been no response after 15 minutes, an additional 1 mg dose (1 mL) of Glucagon for Injection may be administered while waiting for emergency assistance. Pediatric Patients Weighing Less Than 20 kg • The recommended dosage is 0.5 mg (0.5 mL) or dose equivalent to 20 mcg/kg to 30 mcg/kg injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks. Alternatively, healthcare providers may administer the dose intravenously. • If there has been no response after 15 minutes, an additional 0.5 mg dose (0.5 mL) of Glucagon for Injection may be administered while waiting for emergency assistance. 2.3 Important Administration Instructions for Using Glucagon for Injection as a Diagnostic Aid • Reconstitute Glucagon for Injection with 1 mL of diluent. • Swirl the vial gently until the powder is completely dissolved and no particles remain in the fluid. The reconstituted solution should be clear and of a water-like consistency at time of use. Inspect visually for particulate matter and discoloration. If the resulting solution is cloudy or contains particulate matter do not use. • Withdraw the correct dose of Glucagon for Injection. • The reconstituted solution is 1 mg per mL glucagon. • Immediately after reconstitution, inject the solution intravenously or intramuscularly into upper arm, thigh, or buttocks. • Discard unused portion. • After the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure. 2.4 Dosage in Adults for Use as a Diagnostic Aid • Doses required for relaxation of the stomach, duodenum, and small bowel, depend on the onset and duration of effect required for the examination [see Pharmacodynamics (12.2) ] . • The usual dose for relaxation of the stomach, duodenum and small bowel is 0.25 mg to 0.5 mg given intravenously or 1 mg given intramuscularly, but up to 2 mg intravenously or intramuscularly may be used if required (2 mg doses produce a higher rate of nausea and vomiting than lower doses) [see Adverse Reactions (6) ] . • For the stomach because it is less sensitive to the effect of glucagon, 0.5 mg intravenous or 2 mg intramuscular doses are recommended. • For the examination of the colon, it is recommended that a 2 mg dose be administered intramuscularly approximately 10 minutes prior to the procedure."],"spl_product_data_elements":["Glucagon glucagon Glucagon glucagon glucagon glucagon LACTOSE, UNSPECIFIED FORM hydrochloric acid Diluting Solution for Glucagon diluent glycerin water hydrochloric acid"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Glucagon for Injection, USP is a white to off white lyophilized powder or plug supplied as follows: • Single-dose vial containing 1 mg Glucagon for Injection, USP with a pre-filled syringe containing 1 mL of diluent for Glucagon. For Injection: single-dose vial containing 1 mg Glucagon for Injection, USP with a prefilled syringe containing 1 mL of diluent for Glucagon ( 3 )"],"instructions_for_use_table":["<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"50%\"/><col width=\"50%\"/><tbody><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>sweating </item><item><caption>&#x2022;</caption>drowsiness</item><item><caption>&#x2022;</caption>dizziness </item><item><caption>&#x2022;</caption>sleep disturbances </item><item><caption>&#x2022;</caption>irregular heartbeat </item><item><caption>&#x2022;</caption>anxiety </item><item><caption>&#x2022;</caption>tremor </item><item><caption>&#x2022;</caption>blurred vision </item><item><caption>&#x2022;</caption>hunger</item><item><caption>&#x2022;</caption>slurred speech </item><item><caption>&#x2022;</caption>restlessness</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>depressed mood </item><item><caption>&#x2022;</caption>tingling in the hands, feet, lips or tongue. </item><item><caption>&#x2022;</caption>irritability </item><item><caption>&#x2022;</caption>abnormal behavior </item><item><caption>&#x2022;</caption>lightheadedness </item><item><caption>&#x2022;</caption>unsteady movement </item><item><caption>&#x2022;</caption>inability to concentrate </item><item><caption>&#x2022;</caption>personality change </item><item><caption>&#x2022;</caption>headache</item></list></td></tr></tbody></table>","<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"50%\"/><col width=\"50%\"/><tbody><tr><td valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>confusion </item><item><caption>&#x2022;</caption>unconsciousness</item></list></td><td valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>seizures</item><item><caption>&#x2022;</caption>death</item></list></td></tr></tbody></table>"],"spl_patient_package_insert":["PATIENT INFORMATION Glucagon (GLOO-ka-gon) for Injection, USP for subcutaneous, intramuscular, or intravenous use What is Glucagon for Injection? Glucagon for Injection is a prescription medicine used: • to treat very low blood sugar (severe hypoglycemia) in people with diabetes mellitus. • to stop movement in the intestines in people receiving radiology exams. Who should not use Glucagon for Injection? Do not use Glucagon for Injection if: • you have a tumor in the gland on top of your kidneys (adrenal gland) called a pheochromocytoma. • you have a tumor in your pancreas called an insulinoma. • you have a tumor in your pancreas called a glucagonoma because it could cause low blood sugar when used for your radiology exam • you are allergic to glucagon or lactose or any of the ingredients in Glucagon for Injection. See the end of this Patient Information leaflet for a complete list of ingredients in Glucagon for Injection . Before using Glucagon for Injection, tell your healthcare provider about all of your medical conditions, including if you: • have adrenal problems. • have pancreas problems. • have not had anything to eat or have not had a drink of water for a long time (prolonged fasting or starvation). • have low blood sugar that does not go away (chronic hypoglycemia). • have heart problems. • are pregnant or plan to become pregnant. It is not known if Glucagon will harm your unborn baby. • are breastfeeding or plan to breastfeed. It is not known if Glucagon passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Glucagon may affect the way other medicines work, and other medicines may affect how Glucagon works. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I use Glucagon for Injection? • Read the detailed Instructions for Use that come with Glucagon for Injection. • Use Glucagon for Injection exactly how and when your healthcare provider tells you to use it. • Make sure you and your caregiver knows where you keep your Glucagon for Injection and how to use Glucagon for Injection the right way before you need their help. • Act quickly. Having very low blood sugar for a period of time may be harmful. • After Glucagon is mixed, make sure it is clear and of water-like consistency. Do not use if it has particles or is discolored. • After giving Glucagon for Injection the caregiver should call for emergency medical help right away. • Turn the person on their side to prevent them from choking. • If the person does not respond after 15 minutes, another dose may be given, if available while waiting for emergency medical help. • Eat sugar or a sugar sweetened product such as a regular soft drink or fruit juice as soon as you are able to swallow. Tell your healthcare provider each time you use Glucagon for Injection. Your healthcare provider may need to change the dose of your diabetes medicines. What are the possible side effects of Glucagon for Injection? Glucagon may cause serious side effects, including: • High blood pressure . Glucagon can cause high blood pressure in certain people with tumors in their adrenal glands called pheochromocytoma. • Low blood sugar . Glucagon can cause low blood sugar in people with tumors in their pancreas called insulinomas and glucagonomas. Signs and symptoms of low blood sugar may include: • sweating • drowsiness • dizziness • sleep disturbances • irregular heartbeat • anxiety • tremor • blurred vision • hunger • slurred speech • restlessness • depressed mood • tingling in the hands, • feet, lips or tongue • irritability • abnormal behavior • lightheadedness • unsteady movement • inability to concentrate • personality changes • headache Very low blood sugar can cause confusion, seizures, passing out (loss of consciousness) and death. Talk to your healthcare provider about how to tell if you have low blood sugar and what to do if this happens while using Glucagon for Injection. Know your symptoms of low blood sugar. Follow your healthcare provider’s instructions for treat low blood sugar. • Serious allergic reactions. Call your healthcare provider or get medical help right away if you have a serious allergic reaction including: • rash • difficulty breathing • low blood pressure • High blood sugar. If you receive Glucagon for Injection before your radiology exam, it can cause high blood sugar. Your healthcare provider will monitor your blood sugar levels during your treatment. • Heart problems. If you have heart problems and receive Glucagon for Injection before your radiology exam, you may have an increase in your blood pressure and pulse while using Glucagon for Injection which could be life threatening. Your healthcare provider will monitor your heart during treatment. The most common side effects of Glucagon for Injection include: • swelling at the injection site • redness at the injection site • vomiting • nausea • decreased blood pressure • weakness • headache • dizziness • pale skin • diarrhea • sleepiness or drowsiness Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Glucagon for Injection. For more information, ask your healthcare provider. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store Glucagon for Injection? Before you mix the Glucagon powder and liquid: • Do not use Glucagon for Injection if the expiration date has passed. • Store Glucagon for Injection at controlled room temperature 20° to 25°C (68° to 77°F) [See USP]. • Do not freeze Glucagon. • Keep Glucagon for Injection in its original package and away from light. After you mix the Glucagon powder and liquid: • Use Glucagon for Injection right away. • Throw away unused Glucagon for Injection. Keep Glucagon for Injection and all medicines out of the reach of children . General Information about the safe and effective use of Glucagon for Injection. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Glucagon for Injection for a condition for which it was not prescribed. Do not give Glucagon for Injection to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Glucagon for Injection that is written for health professionals. What are the ingredients in the Glucagon for Injection? Active Ingredient: Glucagon Inactive ingredients: lactose monohydrate, hydrochloric acid, and water for injection This Patient Information has been approved by the U.S. Food and Drug Administration Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A Manufactured by: Mylan Laboratories Limited Bangalore, India DECEMBER 2024"],"clinical_pharmacology_table":["<table styleCode=\"Noautorules\" width=\"100%\"><caption>Table 2: Dose and Pharmacodynamic properties of Glucagon for Injection as a Diagnostic Aid</caption><col width=\"24%\"/><col width=\"25%\"/><col width=\"24%\"/><col width=\"28%\"/><tbody><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Dose</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Route of  administration</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Time of onset of  action</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Approximate duration of effect</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>0.25 to 0.5 mg</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Intravenous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1 minute</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9 to 17 minutes</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>1 mg</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Intramuscular</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8 to 10 minutes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12 to 27 minutes</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>2 mg<footnote ID=\"_Ref218665811\">*Administration of 2 mg doses produces a higher incidence of nausea and vomiting than do lower doses.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Intravenous</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1 minute</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>22 to 25 minutes</paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>2 mg<footnoteRef IDREF=\"_Ref218665811\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Intramuscular</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>4 to 7 minutes</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>21 to 32 minutes</paragraph></td></tr></tbody></table>"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation. In a rat reproduction study, no embryofetal toxicity was observed with glucagon administered by injection during the period of organogenesis at doses representing up to 40 times the human dose, based on body surface area (mg/m 2 ) (see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In pregnant rats given animal sourced glucagon twice-daily by injection at doses up to 2 mg/kg (up to 40 times the human dose based on body surface area extrapolation, mg/m 2 ) during the period of organogenesis, there was no evidence of increased malformations or embryofetal lethality. 8.2 Lactation Risk Summary There is no information available on the presence of glucagon in human or animal milk, the effects of glucagon on the breastfed child or the effects of glucagon on milk production. However, glucagon is a peptide and would be expected to be broken down to its constituent amino acids in the infant's digestive tract and is therefore, unlikely to cause harm to an exposed infant. 8.4 Pediatric Use The safety and effectiveness of Glucagon for Injection for the treatment of severe hypoglycemia in pediatric patients with diabetes have been established. Safety and effectiveness for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of glucagon did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient when used as a diagnostic aid should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"spl_patient_package_insert_table":["<table width=\"100%\"><col width=\"33%\"/><col width=\"17%\"/><col width=\"17%\"/><col width=\"33%\"/><tbody><tr><td colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Glucagon (GLOO-ka-gon) for Injection, USP </content></paragraph><paragraph><content styleCode=\"bold\">for subcutaneous, intramuscular, or intravenous use</content></paragraph></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What is Glucagon for Injection?</content></paragraph><paragraph><content styleCode=\"bold\"> </content></paragraph><paragraph>Glucagon for Injection is a prescription medicine used: </paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>to treat very low blood sugar (severe hypoglycemia) in people with diabetes mellitus. </item><item><caption>&#x2022;</caption>to stop movement in the intestines in people receiving radiology exams.</item></list></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Who should not use Glucagon for Injection?</content></paragraph><paragraph><content styleCode=\"bold\"> </content></paragraph><paragraph><content styleCode=\"bold\">Do not </content>use Glucagon for Injection if: </paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>you have a tumor in the gland on top of your kidneys (adrenal gland) called a pheochromocytoma.</item><item><caption>&#x2022;</caption>you have a tumor in your pancreas called an insulinoma.</item><item><caption>&#x2022;</caption>you have a tumor in your pancreas called a glucagonoma because it could cause low blood sugar when used for your radiology exam </item><item><caption>&#x2022;</caption>you are allergic to glucagon or lactose or any of the ingredients in Glucagon for Injection. See the end of this Patient Information leaflet for a complete list of ingredients in Glucagon for Injection<content styleCode=\"bold\">.</content></item></list></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Before using Glucagon for Injection, tell your healthcare provider about all of your medical conditions, including if you: </content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>have adrenal problems. </item><item><caption>&#x2022;</caption>have pancreas problems. </item><item><caption>&#x2022;</caption>have not had anything to eat or have not had a drink of water for a long time (prolonged fasting or starvation). </item><item><caption>&#x2022;</caption>have low blood sugar that does not go away (chronic hypoglycemia). </item><item><caption>&#x2022;</caption>have heart problems. </item><item><caption>&#x2022;</caption>are pregnant or plan to become pregnant. It is not known if Glucagon will harm your unborn baby.</item><item><caption>&#x2022;</caption>are breastfeeding or plan to breastfeed. It is not known if Glucagon passes into your breast milk. </item></list><paragraph>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Glucagon may affect the way other medicines work, and other medicines may affect how Glucagon works. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How should I use Glucagon for Injection? </content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Read the detailed <content styleCode=\"bold\">Instructions for Use </content>that come with Glucagon for Injection. </item><item><caption>&#x2022;</caption>Use Glucagon for Injection exactly how and when your healthcare provider tells you to use it. </item><item><caption>&#x2022;</caption>Make sure you and your caregiver knows where you keep your Glucagon for Injection and how to use Glucagon for Injection the right way <content styleCode=\"bold\">before </content>you need their help. </item><item><caption>&#x2022;</caption>Act quickly. Having very low blood sugar for a period of time may be harmful. </item><item><caption>&#x2022;</caption>After Glucagon is mixed, make sure it is clear and of water-like consistency. Do not use if it has particles or is discolored. </item><item><caption>&#x2022;</caption><content styleCode=\"bold\">After giving Glucagon for Injection the caregiver should call for emergency medical help right away. </content></item><item><caption>&#x2022;</caption>Turn the person on their side to prevent them from choking. </item><item><caption>&#x2022;</caption>If the person does not respond after 15 minutes, another dose may be given, if available while waiting for emergency medical help.</item><item><caption>&#x2022;</caption>Eat sugar or a sugar sweetened product such as a regular soft drink or fruit juice as soon as you are able to swallow. </item></list><paragraph><content styleCode=\"bold\">Tell your healthcare provider each time you use Glucagon for Injection. Your healthcare provider may need to change the dose of your diabetes medicines.</content></paragraph></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are the possible side effects of Glucagon for Injection? </content></paragraph><paragraph><content styleCode=\"bold\">Glucagon may cause serious side effects, including:</content></paragraph><paragraph><content styleCode=\"bold\"/></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">High blood pressure</content>. Glucagon can cause high blood pressure in certain people with tumors in their adrenal glands called pheochromocytoma. </item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Low blood sugar</content>. Glucagon can cause low blood sugar in people with tumors in their pancreas called insulinomas and glucagonomas. Signs and symptoms of low blood sugar may include: </item></list></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>sweating</item><item><caption>&#x2022;</caption>drowsiness</item><item><caption>&#x2022;</caption>dizziness</item><item><caption>&#x2022;</caption>sleep disturbances</item><item><caption>&#x2022;</caption>irregular heartbeat</item><item><caption>&#x2022;</caption>anxiety</item><item><caption>&#x2022;</caption>tremor</item></list></td><td colspan=\"2\" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>blurred vision</item><item><caption>&#x2022;</caption>hunger</item><item><caption>&#x2022;</caption>slurred speech</item><item><caption>&#x2022;</caption>restlessness</item><item><caption>&#x2022;</caption>depressed mood</item><item><caption>&#x2022;</caption>tingling in the hands, </item><item><caption>&#x2022;</caption>feet, lips or tongue</item><item><caption>&#x2022;</caption>irritability</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>abnormal behavior</item><item><caption>&#x2022;</caption>lightheadedness</item><item><caption>&#x2022;</caption>unsteady movement</item><item><caption>&#x2022;</caption>inability to concentrate</item><item><caption>&#x2022;</caption>personality changes</item><item><caption>&#x2022;</caption>headache</item></list></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph>Very low blood sugar can cause confusion, seizures, passing out (loss of consciousness) and death. Talk to your healthcare provider about how to tell if you have low blood sugar and what to do if this happens while using Glucagon for Injection. Know your symptoms of low blood sugar. Follow your healthcare provider&#x2019;s instructions for treat low blood sugar.</paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">Serious allergic reactions. </content>Call your healthcare provider or <content styleCode=\"bold\">get medical help right away </content>if you have a serious allergic reaction including: </item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>rash</item><item><caption>&#x2022;</caption>difficulty breathing</item></list></td><td colspan=\"2\" styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>low blood pressure</item></list></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">High blood sugar. </content>If you receive Glucagon for Injection before your radiology exam, it can cause high blood sugar. Your healthcare provider will monitor your blood sugar levels during your treatment. </item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Heart problems. </content>If you have heart problems and receive Glucagon for Injection before your radiology exam, you may have an increase in your blood pressure and pulse while using Glucagon for Injection which could be life threatening. Your <content styleCode=\"bold\">healthcare provider </content>will monitor your heart during treatment. </item></list><paragraph><content styleCode=\"bold\">The most common side effects of Glucagon for Injection include: </content></paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>swelling at the injection site</item><item><caption>&#x2022;</caption>redness at the injection site</item><item><caption>&#x2022;</caption>vomiting</item><item><caption>&#x2022;</caption>nausea</item><item><caption>&#x2022;</caption>decreased blood pressure</item><item><caption>&#x2022;</caption>weakness</item></list></td><td colspan=\"2\" styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>headache</item><item><caption>&#x2022;</caption>dizziness</item><item><caption>&#x2022;</caption>pale skin</item><item><caption>&#x2022;</caption>diarrhea</item><item><caption>&#x2022;</caption>sleepiness or drowsiness</item></list></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Glucagon for Injection. For more information, ask your healthcare provider. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How should I store Glucagon for Injection?</content></paragraph><paragraph><content styleCode=\"bold\"> </content></paragraph><paragraph><content styleCode=\"bold\">Before you mix the Glucagon powder and liquid:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Do not use Glucagon for Injection if the expiration date has passed. </item><item><caption>&#x2022;</caption>Store Glucagon for Injection at controlled room temperature 20&#xB0; to 25&#xB0;C (68&#xB0; to 77&#xB0;F) [See USP].</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Do not freeze Glucagon. </content></item><item><caption>&#x2022;</caption>Keep Glucagon for Injection in its original package and away from light. </item></list><paragraph><content styleCode=\"bold\">After you mix the Glucagon powder and liquid:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Use Glucagon for Injection right away. </item><item><caption>&#x2022;</caption>Throw away unused Glucagon for Injection. </item></list><paragraph><content styleCode=\"bold\">Keep Glucagon for Injection and all medicines out of the reach of children</content>.</paragraph></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General Information about the safe and effective use of Glucagon for Injection.</content></paragraph><paragraph><content styleCode=\"bold\"> </content></paragraph><paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Glucagon for Injection for a condition for which it was not prescribed. Do not give Glucagon for Injection to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Glucagon for Injection that is written for health professionals. </paragraph></td></tr><tr><td colspan=\"4\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are the ingredients in the Glucagon for Injection? </content></paragraph><paragraph><content styleCode=\"bold\"> </content></paragraph><paragraph><content styleCode=\"bold\">Active Ingredient: </content>Glucagon </paragraph><paragraph><content styleCode=\"bold\">Inactive ingredients: </content>lactose monohydrate, hydrochloric acid, and water for injection </paragraph><paragraph> </paragraph><paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration</paragraph><paragraph> </paragraph><paragraph>Manufactured for:</paragraph><paragraph><content styleCode=\"bold\">Mylan Pharmaceuticals Inc.</content></paragraph><paragraph>Morgantown, WV 26505 U.S.A</paragraph><paragraph> </paragraph><paragraph>Manufactured by:</paragraph><paragraph><content styleCode=\"bold\">Mylan Laboratories Limited</content></paragraph><paragraph>Bangalore, India</paragraph><paragraph> </paragraph><paragraph>DECEMBER 2024</paragraph></td></tr></tbody></table>"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL – 1 mg NDC 0378-8067-90 Glucagon Emergency Kit for Low Blood Sugar Glucagon for Injection USP, 1 mg per vial Diluent for Glucagon, 1 mL syringe Rx only 1034120 Must reconstitute vial contents with diluent. IMPORTANT - Read the enclosed insert carefully for directions before using. PHARMACISTS-Please detach 'INFORMATION FOR THE USER' and give to the patient. This kit contains: 1 single-dose vial of Glucagon for Injection, USP: 1 mg glucagon, USP and 49 mg lactose monohydrate; hydrochloric acid may have been added to adjust the pH of glucagon. 1 syringe of diluent for Glucagon: 12 mg/ml glycerin, water for injection, and 1 mg hydrochloric acid. Usual Dose - 1 mg subcutaneously, intramuscularly, or intravenously for adults and pediatric patients weighing more than 20 kg. For smaller pediatric patients, see enclosed insert. DO NOT REMOVE PLASTIC CLIP FROM THE ACCOMPANYING SYRINGE. Mix immediately before use. Add the entire contents of the accompanying syringe into the Glucagon vial. Mix well and gently withdraw the entire contents of the vial back into the syringe. Before Reconstitution: Store at controlled room g temperature 20° to 25° C (68° to 77° F) [See USP]. 􀈚 NON-RETURNABLE. Discard unused portion. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Made in India Code No.: KR/DRUGS/KTK/28/384/2009 1033014 Glucagon Emergency Kit for Low Blood Sugar Container Label Front Glucagon Emergency Kit for Low Blood Sugar Container Label Back"],"package_label_principal_display_panel_table":["<table styleCode=\"Noautorules\" width=\"100%\"><col width=\"100%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>IMPORTANT - Read the enclosed insert carefully for directions before using. </paragraph><paragraph>PHARMACISTS-Please detach &apos;INFORMATION FOR THE USER&apos; and give to the patient.</paragraph></td></tr></tbody></table>"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long term studies in animals to evaluate carcinogenic potential have not been performed. Recombinant glucagon was positive in the bacterial Ames assay. It was determined that an increase in colony counts was related to technical difficulties in running this assay with peptides. Studies in rats have shown that glucagon does not cause impaired fertility."]},"tags":[{"label":"Antihypoglycemic Agent","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glucocorticoid receptor","category":"target"},{"label":"NR3C1","category":"gene"},{"label":"GCGR","category":"gene"},{"label":"GLP1R","category":"gene"},{"label":"H04AA01","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Nasal","category":"route"},{"label":"Injection","category":"form"},{"label":"Powder","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Gastrointestinal Radiography Adjunct","category":"indication"},{"label":"Hypoglycemic disorder","category":"indication"},{"label":"Severe hypoglycaemia in patients with diabetes","category":"indication"},{"label":"Xeris","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"362 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"354 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"313 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"287 reports"},{"date":"","signal":"HYPOGLYCAEMIA","source":"FDA FAERS","actionTaken":"268 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"244 reports"},{"date":"","signal":"TOXICITY TO VARIOUS AGENTS","source":"FDA FAERS","actionTaken":"230 reports"},{"date":"","signal":"HAEMOPTYSIS","source":"FDA FAERS","actionTaken":"214 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"213 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"213 reports"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Hypoglycemia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Vomiting","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Headache","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hyperglycemia","drugRate":"7%","severity":"common","_validated":true},{"effect":"Hypertension","drugRate":"reported","severity":"unknown"},{"effect":"Tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"Injection site edema","drugRate":"7%","severity":"mild","_validated":true},{"effect":"Injection site pain","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Abdominal pain","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Injection site discomfort","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Injection site reaction","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Urticaria","drugRate":"3%","severity":"mild","_validated":true}],"contraindications":["Diabetes mellitus","Glucagonoma","Insulinoma","Pheochromocytoma"],"specialPopulations":{"Pregnancy":"Available data from case reports and small number of observational studies with glucagon use in pregnant women over decades of use have not identified drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Multiple small studies have demonstrated lack of transfer of pancreatic glucagon across the human placental barrier during early gestation. In rat reproduction study, no embryofetal toxicity was observed with glucagon administered by injection during the period of organogenesis at doses representing up to 40 times the human dose, based on body surface area (mg/m2) (see Data).The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.","Geriatric use":"Clinical studies of BAQSIMI did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Limited clinical trial experience has not identified differences in responses between the elderly and younger patients.","Paediatric use":"The safety and effectiveness of GlucaGen for the treatment of severe hypoglycemia in pediatric patients with diabetes have been established.Safety and effectiveness for use as diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Xeris","patents":[{"applNo":"N212097","source":"FDA Orange Book","status":"Active","expires":"Apr 22, 2036","useCode":"U-2742","territory":"US","drugProduct":true,"patentNumber":"9649364","drugSubstance":false},{"applNo":"N212097","source":"FDA Orange Book","status":"Active","expires":"Apr 22, 2036","useCode":"U-2742","territory":"US","drugProduct":true,"patentNumber":"11590205","drugSubstance":false},{"type":"Formulation","number":"10213487","applicant":"AMPHASTAR PHARMACEUTICALS INC","territory":"US","tradeName":"BAQSIMI","expiryDate":"2036-02-16"},{"type":"Formulation","number":"12370241","applicant":"AMPHASTAR PHARMACEUTICALS INC","territory":"US","tradeName":"BAQSIMI","expiryDate":"2036-02-16"},{"type":"Formulation","number":"10765602","applicant":"AMPHASTAR PHARMACEUTICALS INC","territory":"US","tradeName":"BAQSIMI","expiryDate":"2039-09-23"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$223.9247/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$81,733","description":"GLUCAGON 1 MG EMERGENCY KIT","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GLUCAGON","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:38:35.967811+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:38:35.967741+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:38:41.219004+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:38:36.043838+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:38:34.882852+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GLUCAGON","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:38:41.551981+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:38:33.130864+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:38:43.505823+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucagon receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:38:43.077724+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5314342/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:38:42.587291+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA204468","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:38:33.130884+00:00"}},"allNames":"glucagen","offLabel":[],"synonyms":["ogluo","glucagon hydrochloride recombinant","glucagen","glucagon","glucagonoid","glukagon","hyperglycemic-glycogenolytic factor","glucagon hydrochloride","glucagon HCl","glucagon recombinant"],"timeline":[{"date":"1960-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from XERIS PHARMACEUTICALS IRELAND LIMITED to Xeris"},{"date":"1960-11-14","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"1998-09-11","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Lilly)"},{"date":"2019-07-24","type":"positive","source":"FDA Orange Book","milestone":"Baqsimi approved — 3MG"},{"date":"2020-03-25","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Eli Lilly Japan K.K.)"},{"date":"2021-02-02","type":"positive","source":"DrugCentral","milestone":"EMA approval (Xeris Pharmaceuticals Ireland Limited)"},{"date":"2024-12-12","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"}],"aiSummary":"Glucagen (GLUCAGON) is a small molecule antihypoglycemic agent developed by XERIS PHARMACEUTICALS IRELAND LIMITED and currently owned by Xeris. It targets the glucocorticoid receptor and is used to treat hypoglycemic disorders, severe hypoglycaemia in patients with diabetes, and as an adjunct for gastrointestinal radiography. Glucagen was FDA approved in 1960 and is available as a generic medication. The commercial status of Glucagen is off-patent, with multiple generic manufacturers. Key safety considerations include its use in patients with diabetes and potential interactions with other medications.","approvals":[{"date":"1960-11-14","orphan":false,"company":"","regulator":"FDA"},{"date":"2020-03-25","orphan":false,"company":"Eli Lilly Japan K.K.","regulator":"PMDA"},{"date":"2021-02-02","orphan":false,"company":"XERIS PHARMACEUTICALS IRELAND LIMITED","regulator":"EMA"}],"brandName":"Glucagen","ecosystem":[{"indication":"Gastrointestinal Radiography Adjunct","otherDrugs":[{"name":"metoclopramide","slug":"metoclopramide","company":"Baxter Hlthcare Corp"},{"name":"silicon dioxide","slug":"silicon-dioxide","company":""}],"globalPrevalence":null},{"indication":"Hypoglycemic disorder","otherDrugs":[],"globalPrevalence":null},{"indication":"Severe hypoglycaemia in patients with diabetes","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Glucocorticoid receptor","novelty":"First-in-class","targets":[{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"},{"gene":"GCGR","source":"DrugCentral","target":"Glucagon receptor","protein":"Glucagon receptor"},{"gene":"GLP1R","source":"DrugCentral","target":"Glucagon-like peptide 1 receptor","protein":"Glucagon-like peptide 1 receptor"}],"modality":"Small Molecule","drugClass":"Antihypoglycemic Agent","explanation":"Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon.","oneSentence":"Glucagen works by stimulating the release of glucose from stored energy sources in the body.","technicalDetail":"Glucagon is a peptide hormone that stimulates glycogenolysis and gluconeogenesis, leading to an increase in blood glucose levels through the release of glucose from stored glycogen and the production of new glucose from non-carbohydrate sources."},"commercial":{"launchDate":"1960","_launchSource":"DrugCentral (FDA 1960-11-14, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2994","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GLUCAGON","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GLUCAGON","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T14:56:18.531484","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:38:46.513095+00:00","fieldsConflicting":4,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"dasiglucagon","drugSlug":"dasiglucagon","fdaApproval":"2021-03-22","patentExpiry":"Jan 6, 2034","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"glucagon","indications":{"approved":[{"name":"Gastrointestinal Radiography Adjunct","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null},{"name":"Hypoglycemic disorder","source":"DrugCentral","snomedId":237630007,"regulator":"FDA","eligibility":null},{"name":"Severe hypoglycaemia in patients with diabetes","source":"DrugCentral","snomedId":237633009,"regulator":"FDA","eligibility":"pediatric and adult patients with diabetes ages 2 years and above"}],"offLabel":[],"pipeline":[]},"currentOwner":"Xeris","drugCategory":"mature","labelChanges":[],"relatedDrugs":[{"drugId":"dasiglucagon","brandName":"dasiglucagon","genericName":"dasiglucagon","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02817659","phase":"PHASE1","title":"To Determine Tolerability to Glucagon Infusion in Obese Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"AdventHealth Translational Research Institute","startDate":"2016-11-01","conditions":["Obesity"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT06774079","phase":"PHASE4","title":"Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-03-05","conditions":["Crohn Disease"],"enrollment":24,"completionDate":"2027-03-05"},{"nctId":"NCT07046819","phase":"PHASE2","title":"Tirzepatide in MetALD","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2026-04-02","conditions":["Metabolic Alcohol-associated Liver Disease","Alcohol Use Disorder"],"enrollment":120,"completionDate":"2026-07-30"},{"nctId":"NCT07240246","phase":"NA","title":"Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation","startDate":"2025-10-24","conditions":["GLP-1","Obesity &Amp; Overweight","Dietary Supplement"],"enrollment":40,"completionDate":"2026-05-11"},{"nctId":"NCT06171152","phase":"EARLY_PHASE1","title":"Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues","status":"SUSPENDED","sponsor":"University of Chicago","startDate":"2024-01-26","conditions":["Multiple Sclerosis","Long COVID","Long Covid19","Obese","Obesity","Obesity, Morbid","Acute Leukemia in Remission"],"enrollment":30,"completionDate":"2027-10-01"},{"nctId":"NCT03139305","phase":"PHASE1","title":"Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"AdventHealth Translational Research Institute","startDate":"2017-10-24","conditions":["Obesity"],"enrollment":30,"completionDate":"2027-02"},{"nctId":"NCT07349641","phase":"PHASE2","title":"A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-06","conditions":["Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia","FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma"],"enrollment":55,"completionDate":"2029-12-31"},{"nctId":"NCT07284901","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2026-01-12","conditions":["Obesity With Diabetes","Overweight With Diabetes"],"enrollment":1700,"completionDate":"2028-04-24"},{"nctId":"NCT07431086","phase":"PHASE2","title":"Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-16","conditions":["Overweight or Obesity"],"enrollment":120,"completionDate":"2026-12-18"},{"nctId":"NCT07497399","phase":"PHASE2","title":"Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04","conditions":["Multiple Sclerosis"],"enrollment":120,"completionDate":"2029-12"},{"nctId":"NCT06732245","phase":"PHASE2","title":"Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese","status":"NOT_YET_RECRUITING","sponsor":"Biomed Industries, Inc.","startDate":"2026-08-15","conditions":["Obesity and Overweight"],"enrollment":224,"completionDate":"2027-12-15"},{"nctId":"NCT07446998","phase":"PHASE2","title":"Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","status":"RECRUITING","sponsor":"Veru Inc.","startDate":"2026-03","conditions":["Obesity & Overweight","Mobility Disability","HOMA-IR"],"enrollment":200,"completionDate":"2027-12"},{"nctId":"NCT05933499","phase":"PHASE2","title":"Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-11-05","conditions":["Obesity"],"enrollment":63,"completionDate":"2029-03-31"},{"nctId":"NCT07497880","phase":"PHASE2","title":"Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity","status":"NOT_YET_RECRUITING","sponsor":"Kailera","startDate":"2026-04-01","conditions":["Obesity","Overweight"],"enrollment":320,"completionDate":"2027-07-07"},{"nctId":"NCT06751589","phase":"EARLY_PHASE1","title":"A Study of a Weight Loss Intervention in People With Endometrial Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-12-19","conditions":["Endometrial Cancer"],"enrollment":36,"completionDate":"2026-12"},{"nctId":"NCT06047548","phase":"PHASE3","title":"A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-09-20","conditions":["Overweight","Obesity"],"enrollment":441,"completionDate":"2026-01-20"},{"nctId":"NCT07492563","phase":"","title":"Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay","status":"NOT_YET_RECRUITING","sponsor":"LABORATORIOS INDUFAR","startDate":"2026-03","conditions":["Obesity","Type 2 Diabetes Mellitus","Overweight With Comorbidities"],"enrollment":300,"completionDate":"2027-10"},{"nctId":"NCT06937099","phase":"PHASE3","title":"Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-06-26","conditions":["Crohn's Disease","Obesity or Overweight"],"enrollment":290,"completionDate":"2028-05"},{"nctId":"NCT07220473","phase":"PHASE2","title":"Tirzepatide to Slow Biological Aging","status":"RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2026-02-27","conditions":["Aging","LONGEVITY 1"],"enrollment":90,"completionDate":"2028-01"},{"nctId":"NCT06439277","phase":"PHASE3","title":"A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-06-03","conditions":["Obesity","Weight Gain"],"enrollment":300,"completionDate":"2030-12"},{"nctId":"NCT06937086","phase":"PHASE3","title":"Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-06-26","conditions":["Ulcerative Colitis","Obesity or Overweight"],"enrollment":350,"completionDate":"2028-04"},{"nctId":"NCT06143956","phase":"PHASE2","title":"A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-11-17","conditions":["Obesity","Overweight"],"enrollment":1217,"completionDate":"2026-09"},{"nctId":"NCT07218445","phase":"PHASE4","title":"The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-04","conditions":["Obesity","Menopause Hot Flashes"],"enrollment":40,"completionDate":"2027-09-18"},{"nctId":"NCT06651177","phase":"PHASE2","title":"Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"T. John Winhusen, PhD","startDate":"2026-01-29","conditions":["Opioid Use Disorder","Opioid Use Disorder, Moderate","Opioid Use Disorder, Severe"],"enrollment":310,"completionDate":"2027-10-31"},{"nctId":"NCT07491133","phase":"NA","title":"Effect of Ambient Temperature on Blood Glucose and Insulin Absorption in Adults With Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2026-03","conditions":["Type 1 Diabetes Mellitus"],"enrollment":30,"completionDate":"2027-07"},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":["Endometrial Cancer","Endometrial Cancer Stage I","Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","Atypical Endometrial Hyperplasia","Endometrial Intraepithelial Neoplasia","Obesity & Overweight","Obesity (BMI > 35)"],"enrollment":82,"completionDate":"2026-12"},{"nctId":"NCT06037252","phase":"PHASE2","title":"A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-09-21","conditions":["Type 2 Diabetes","Obesity"],"enrollment":414,"completionDate":"2026-10"},{"nctId":"NCT07165028","phase":"PHASE3","title":"A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-15","conditions":["Metabolic Dysfunction-Associated Steatotic Liver Disease"],"enrollment":4500,"completionDate":"2032-08"},{"nctId":"NCT06857942","phase":"PHASE4","title":"A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-19","conditions":["Psoriasis","Overweight or Obesity"],"enrollment":200,"completionDate":"2028-05"},{"nctId":"NCT07247084","phase":"PHASE4","title":"A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-24","conditions":["Obesity"],"enrollment":3000,"completionDate":"2032-07"},{"nctId":"NCT05663515","phase":"","title":"A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":["Pancreatic Cancer"],"enrollment":24000,"completionDate":"2026-10-01"},{"nctId":"NCT07481747","phase":"PHASE3","title":"Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":["Obesity","Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities"],"enrollment":2539,"completionDate":"2028-03-17"},{"nctId":"NCT07483801","phase":"PHASE4","title":"DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies","status":"NOT_YET_RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2026-03","conditions":["Cardiovascular Diseases"],"enrollment":112,"completionDate":"2028-04"},{"nctId":"NCT07107334","phase":"PHASE2","title":"A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia","status":"RECRUITING","sponsor":"University of Florida","startDate":"2026-03","conditions":["Endometrioid Endometrial Adenocarcinoma"],"enrollment":20,"completionDate":"2029-11"},{"nctId":"NCT07281937","phase":"PHASE2","title":"A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","status":"ACTIVE_NOT_RECRUITING","sponsor":"Verdiva Bio Dev Limited","startDate":"2025-11-25","conditions":["Obesity","Overweight"],"enrollment":206,"completionDate":"2026-08"},{"nctId":"NCT07207148","phase":"","title":"People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-11-15","conditions":["Multiple Sclerosis"],"enrollment":100,"completionDate":"2028-08-31"},{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":["Type 2 Diabetes (T2D)"],"enrollment":678,"completionDate":"2026-09-18"},{"nctId":"NCT05119179","phase":"PHASE4","title":"Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-11-22","conditions":["PreDiabetes"],"enrollment":300,"completionDate":"2026-10-31"},{"nctId":"NCT07195994","phase":"NA","title":"A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes","status":"RECRUITING","sponsor":"QuickSilver Scientific","startDate":"2026-02-05","conditions":["Prediabetes / Type 2 Diabetes"],"enrollment":90,"completionDate":"2026-09"},{"nctId":"NCT07284979","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2025-12-30","conditions":["Obesity"],"enrollment":1200,"completionDate":"2028-04-17"},{"nctId":"NCT06762314","phase":"PHASE2","title":"Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-01-20","conditions":["Diabetes"],"enrollment":105,"completionDate":"2028-11-20"},{"nctId":"NCT07257484","phase":"PHASE4","title":"Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors","status":"NOT_YET_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2026-04-06","conditions":["Obesity (Disorder)","Breast Cancer"],"enrollment":30,"completionDate":"2027-12-30"},{"nctId":"NCT07212868","phase":"PHASE1","title":"The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-02-25","conditions":["Non-Diabetic"],"enrollment":150,"completionDate":"2030-06-30"},{"nctId":"NCT07468552","phase":"PHASE2","title":"Trial of Tirzepatide for the Treatment of Cannabis Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2026-11-15","conditions":["Cannabis Use Disorder"],"enrollment":100,"completionDate":"2028-11-15"},{"nctId":"NCT07455825","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":["Healthy Participants"],"enrollment":64,"completionDate":"2026-06-01"},{"nctId":"NCT07465926","phase":"","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2017-01-01","conditions":["Cardiovascular-kidney-metabolic Syndrome","Cardiovascular Disease Risk Factor","Kidney Disease","Type 2 Diabetes","Obesity & Overweight"],"enrollment":451036,"completionDate":"2026-01-31"},{"nctId":"NCT07467447","phase":"PHASE2","title":"Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-15","conditions":["Obesity"],"enrollment":300,"completionDate":"2028-02-17"},{"nctId":"NCT06252493","phase":"","title":"Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-12-19","conditions":["Crohn Disease"],"enrollment":25,"completionDate":"2029-12-19"},{"nctId":"NCT07463846","phase":"PHASE1,PHASE2","title":"A Study to Evaluate ALN-2232 in Participants With Obesity","status":"RECRUITING","sponsor":"Alnylam Pharmaceuticals","startDate":"2026-03-02","conditions":["Obesity"],"enrollment":156,"completionDate":"2028-03-01"},{"nctId":"NCT06982378","phase":"","title":"GLP-1 RA on Liver OMICS in MASLD","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-07","conditions":["NAFLD","Diabetes","Obesity"],"enrollment":30,"completionDate":"2028-12"},{"nctId":"NCT06246799","phase":"PHASE3","title":"Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-11-07","conditions":["Type 2 Diabetes (Adult Onset)"],"enrollment":256,"completionDate":"2029-06-30"},{"nctId":"NCT06162715","phase":"PHASE2,PHASE3","title":"GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2024-10-30","conditions":["Severe Obesity","Obesity","BMI Greater Than 30"],"enrollment":30,"completionDate":"2027-12"},{"nctId":"NCT07457424","phase":"","title":"Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College Dublin","startDate":"2022-02-17","conditions":["Metabolic Disease","Obesity & Overweight"],"enrollment":140,"completionDate":"2027-01-31"},{"nctId":"NCT07249554","phase":"PHASE2","title":"Combination Therapy for Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-05","conditions":["Alcohol Use Disorder"],"enrollment":45,"completionDate":"2028-06"},{"nctId":"NCT07458269","phase":"PHASE2","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Kailera","startDate":"2026-03","conditions":["Obesity"],"enrollment":250,"completionDate":"2027-06"},{"nctId":"NCT05965908","phase":"PHASE3","title":"Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-01-30","conditions":["Polycystic Ovary"],"enrollment":150,"completionDate":"2025-03-30"},{"nctId":"NCT05254314","phase":"PHASE2","title":"Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-10-11","conditions":["Asthma"],"enrollment":100,"completionDate":"2026-12"},{"nctId":"NCT05500586","phase":"PHASE1,PHASE2","title":"The Effects of Glucagon on Hepatic Metabolism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adrian Vella","startDate":"2022-10-20","conditions":["Obesity","Type2diabetes","NAFLD"],"enrollment":21,"completionDate":"2026-03-31"},{"nctId":"NCT07299084","phase":"PHASE1","title":"A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-01-14","conditions":["Diabetes Mellitus, Type 2","Overweight","Obesity"],"enrollment":40,"completionDate":"2026-10"},{"nctId":"NCT05681299","phase":"PHASE4","title":"Effects of GH and Lirglutide on AgRP","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-05-01","conditions":["Healthy","Growth Hormone Deficiency"],"enrollment":40,"completionDate":"2028-04-30"},{"nctId":"NCT06747468","phase":"PHASE3","title":"Avexitide for Treatment of Post-Bariatric Hypoglycemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2025-04-29","conditions":["Post Bariatric Hypoglycemia"],"enrollment":75,"completionDate":"2026-10"},{"nctId":"NCT06512584","phase":"PHASE3","title":"Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition","status":"RECRUITING","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","startDate":"2024-09-03","conditions":["Short Bowel Syndrome"],"enrollment":72,"completionDate":"2026-04-27"},{"nctId":"NCT07444203","phase":"","title":"Transformative Research in Diabetic Nephropathy 2.0","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-11-12","conditions":["Diabetic Nephropathies","Kidney Diseases","Renal Insufficiency, Chronic","Diabetes Mellitus, Type 2"],"enrollment":200,"completionDate":"2028-11-12"},{"nctId":"NCT07443956","phase":"NA","title":"Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2026-02-24","conditions":["Psoriatic Arthritis (PsA)","Obesity & Overweight"],"enrollment":45,"completionDate":"2030-05"},{"nctId":"NCT07284875","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2025-12-18","conditions":["Obesity","Overweight"],"enrollment":1800,"completionDate":"2028-03-27"},{"nctId":"NCT07438444","phase":"PHASE4","title":"A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-03","conditions":["Diabetes Mellitus, Type 2","Obesity","Overweight"],"enrollment":344,"completionDate":"2027-10"},{"nctId":"NCT07439536","phase":"PHASE4","title":"Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2024-07-01","conditions":["Liver Cirrhosis With Diabetes"],"enrollment":64,"completionDate":"2025-10-01"},{"nctId":"NCT07304141","phase":"","title":"Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2023-12-20","conditions":["Obesity (Disorder)","Child Obesity"],"enrollment":128,"completionDate":"2025-12-12"},{"nctId":"NCT06759701","phase":"EARLY_PHASE1","title":"Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-07-02","conditions":["Diabetes","Prostate Cancer"],"enrollment":30,"completionDate":"2028-12-31"},{"nctId":"NCT07427251","phase":"PHASE4","title":"The Postprandial Hypo-Avoid Study","status":"NOT_YET_RECRUITING","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2026-03-15","conditions":["Type 1 Diabetes Mellitus"],"enrollment":18,"completionDate":"2028-05-01"},{"nctId":"NCT07095517","phase":"PHASE1","title":"Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-02-24","conditions":["Colorectal Cancer Prevention","Colorectal Adenoma"],"enrollment":20,"completionDate":"2028-12-31"},{"nctId":"NCT06027567","phase":"PHASE4","title":"The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure","status":"COMPLETED","sponsor":"Rigmor Højland Jensen","startDate":"2022-09-02","conditions":["Idiopathic Intracranial Hypertension","Intracranial Pressure","Obesity","Pseudotumor Cerebri Syndrome","Papilledema","Weight Loss"],"enrollment":38,"completionDate":"2025-10-28"},{"nctId":"NCT06546384","phase":"NA","title":"GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease","status":"NOT_YET_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2026-05-01","conditions":["Adiposity","Fatty Liver","Alcohol Use Disorder"],"enrollment":64,"completionDate":"2027-04-30"},{"nctId":"NCT07027995","phase":"NA","title":"Food and Fitness With Medicine (FFWM)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2026-01-14","conditions":["Cardiovascular Kidney Metabolic Syndrome","Type 2 Diabetes"],"enrollment":200,"completionDate":"2029-03"},{"nctId":"NCT07423247","phase":"PHASE4","title":"Tirzepatide (Spartina) in Obese Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2026-01-01","conditions":["Tirzepatide"],"enrollment":30,"completionDate":"2026-09"},{"nctId":"NCT07317115","phase":"NA","title":"Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes","status":"RECRUITING","sponsor":"GT Metabolic Solutions, Inc.","startDate":"2026-03","conditions":["Obesity (Disorder)","Obesity & Overweight","Type 2 Diabetes (T2DM)"],"enrollment":20,"completionDate":"2028-06"},{"nctId":"NCT07417618","phase":"","title":"INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-01-27","conditions":["Type 2 Diabetes","Overweight","ASCVD"],"enrollment":60000,"completionDate":"2026-03"},{"nctId":"NCT03363464","phase":"","title":"Comparative Effectiveness of Empagliflozin in the US","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2017-10-16","conditions":["Diabetes Mellitus, Type 2"],"enrollment":230000,"completionDate":"2026-04-30"},{"nctId":"NCT06914895","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-04-25","conditions":["Type 1 Diabetes","Obesity","Overweight"],"enrollment":905,"completionDate":"2026-12"},{"nctId":"NCT07101939","phase":"PHASE2","title":"A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)","status":"RECRUITING","sponsor":"Actimed Therapeutics Ltd","startDate":"2025-06-23","conditions":["Obesity","Muscle Loss"],"enrollment":120,"completionDate":"2027-03"},{"nctId":"NCT06470295","phase":"EARLY_PHASE1","title":"Effect of C-peptide on Hypoglycemic Counterregulation","status":"RECRUITING","sponsor":"University of Cincinnati","startDate":"2024-06-01","conditions":["Hypoglycemia","Type 1 Diabetes"],"enrollment":38,"completionDate":"2028-01-01"},{"nctId":"NCT06962280","phase":"PHASE3","title":"A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-05-12","conditions":["Type 1 Diabetes","Obesity","Overweight"],"enrollment":465,"completionDate":"2027-07"},{"nctId":"NCT07411378","phase":"PHASE2","title":"Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.","status":"NOT_YET_RECRUITING","sponsor":"Biophytis","startDate":"2026-07","conditions":["Muscle Wasting","Obesity & Overweight","Obesity"],"enrollment":164,"completionDate":"2027-08"},{"nctId":"NCT05264727","phase":"PHASE4","title":"Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-05-30","conditions":["Healthy","Type 2 Diabetes","Obesity"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT06517212","phase":"PHASE2","title":"Tirzepatide Weight Loss for MRD+ Early Breast Cancer","status":"RECRUITING","sponsor":"Baylor Research Institute","startDate":"2024-11-26","conditions":["Breast Cancer","Breast Neoplasms","Breast Cancers"],"enrollment":48,"completionDate":"2030-12-31"},{"nctId":"NCT06965413","phase":"PHASE2","title":"A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-05","conditions":["Obesity","Overweight","Overweight With One Weight Related Comorbidity"],"enrollment":285,"completionDate":"2027-07-23"},{"nctId":"NCT06608433","phase":"NA","title":"Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-01-16","conditions":["Healthy Volunteer Study","HPA","Cortisol Deficiency","Adrenal Insufficiency"],"enrollment":22,"completionDate":"2025-11-30"},{"nctId":"NCT07400783","phase":"NA","title":"TED_ORG: Study on Short Bowel Syndrome","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2024-10-30","conditions":["Short Bowel Syndrome (SBS)"],"enrollment":50,"completionDate":"2026-10"},{"nctId":"NCT06864026","phase":"PHASE4","title":"A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-06","conditions":["Psoriatic Arthritis","Overweight or Obesity"],"enrollment":200,"completionDate":"2027-11"},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":["Type 2 Diabetes","Comparative Effectiveness of Glycemia-lowering Medications"],"enrollment":7850,"completionDate":"2021-04-30"},{"nctId":"NCT06939088","phase":"PHASE2","title":"Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder","status":"RECRUITING","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2025-05-05","conditions":["Alcohol Use Disorder","Alcohol Abuse/Dependence","Alcohol Dependence","Alcoholism","Schizophrenia Disorders","Schizophrenia and Disorders With Psychotic Features","Schizophrenia and Schizophrenia Spectrum Psychosis","Schizophrenia"],"enrollment":108,"completionDate":"2028-12-31"},{"nctId":"NCT07398300","phase":"NA","title":"Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2026-03-12","conditions":["Type 2 Diabetes","Healhty"],"enrollment":36,"completionDate":"2027-05"},{"nctId":"NCT02674893","phase":"PHASE4","title":"Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2014-02-04","conditions":["Type 2 Diabetes","Overweight"],"enrollment":48,"completionDate":"2016-08-31"},{"nctId":"NCT06558422","phase":"PHASE1","title":"Human Models of Selective Insulin Resistance: Pancreatic Clamp","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2027-01-01","conditions":["Insulin Resistance","Hyperinsulinemia","Metabolic Dysfunction Associated Steatotic Liver Disease","Non-Alcoholic Fatty Liver Disease","Prediabetic State","Obesity"],"enrollment":36,"completionDate":"2029-02-28"},{"nctId":"NCT02721888","phase":"PHASE4","title":"Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2012-07-10","conditions":["Type 2 Diabetes"],"enrollment":127,"completionDate":""},{"nctId":"NCT06986603","phase":"PHASE4","title":"Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joslin Diabetes Center","startDate":"2024-11-26","conditions":["Hypoglycemia","Hypoglycemia, Reactive","Bariatric Surgery"],"enrollment":28,"completionDate":"2026-09-01"},{"nctId":"NCT07136714","phase":"PHASE4","title":"Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity","status":"RECRUITING","sponsor":"Nordsjaellands Hospital","startDate":"2025-09-11","conditions":["Major Depressive Disorder"],"enrollment":116,"completionDate":"2027-09"},{"nctId":"NCT06131437","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-11-27","conditions":["Obesity"],"enrollment":809,"completionDate":"2026-01-09"},{"nctId":"NCT07202247","phase":"PHASE2","title":"Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-01-23","conditions":["Prostate Carcinoma","Recurrent Prostate Carcinoma"],"enrollment":60,"completionDate":"2028-04-09"},{"nctId":"NCT03498001","phase":"NA","title":"Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2018-04-16","conditions":["Type II Diabetes"],"enrollment":42,"completionDate":"2023-12-20"}],"_emaApprovals":[{"date":"2021-02-02","status":"Authorised","company":"XERIS PHARMACEUTICALS IRELAND LIMITED"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Subcutaneous, Intravenous, Nasal","formulation":"Injection, Powder","formulations":[{"form":"INJECTION, POWDER, FOR SOLUTION","route":"SUBCUTANEOUS","productName":"GlucaGen"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Glucagon"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Gvoke HypoPen\n0.5 mg Auto-Injector"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Gvoke HypoPen\n1 mg Auto-Injector"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Gvoke Kit"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Gvoke KitVial"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Gvoke PFS0.5 mg Pre-filled Syringe"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Gvoke PFS1 mg Pre-filled Syringe"},{"form":"POWDER","route":"NASAL","productName":"Baqsimi"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"14121","NDDF":"002065","UNII":"76LA80IG2G","CHEBI":"CHEBI:5391","VANDF":"4017456","INN_ID":"933","RXNORM":"151823","UMLSCUI":"C0017687","chemblId":"CHEMBL5314342","ChEMBL_ID":"CHEMBL1201618","KEGG_DRUG":"D00116","DRUGBANK_ID":"DB00040","PUBCHEM_CID":"16132283","SNOMEDCT_US":"10712001","IUPHAR_LIGAND_ID":"1136","SECONDARY_CAS_RN":"19179-82-9","MESH_DESCRIPTOR_UI":"D005934"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1960-","companyName":"Xeris Pharmaceuticals Ireland Limited","relationship":"Original Developer"},{"period":"present","companyName":"Xeris","relationship":"Current Owner"},{"period":"2020","companyName":"Eli Lilly Japan K.K.","relationship":"PMDA Licensee"}],"publicationCount":53687,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"H04AA01","allCodes":["H04AA01"]},"biosimilarFilings":[],"originalDeveloper":"Xeris Pharmaceuticals Ireland Limited","recentPublications":[{"date":"2026 Mar 30","pmid":"41905933","title":"Effects of plant flavonoids and selenium on pancreatic hormones and glucose homeostasis in autoimmune thyroiditis.","journal":"Experimental animals"},{"date":"2026 Mar 27","pmid":"41905685","title":"A cross-sectional study of prescribing rates for SGLT2 inhibitors and GLP-1 receptor agonists among primary care clinics with and without embedded pharmacists.","journal":"Journal of the American Pharmacists Association : JAPhA"},{"date":"2026 Mar 27","pmid":"41905619","title":"Obesity Management in End-Stage Kidney Disease: Pathways to Improve Kidney Transplant Access.","journal":"American journal of kidney diseases : the official journal of the National Kidney Foundation"},{"date":"2026 Mar 27","pmid":"41905447","title":"Genetic Variations in GLP-1R: Impact on Diabetes and Obesity Therapeutics.","journal":"European journal of pharmacology"},{"date":"2026 Mar 29","pmid":"41904760","title":"Tirzepatide mitigates atherosclerosis progression and modulates oxLDL-mediated proatherogenic effects in macrophages: evidence for M1/M2 homeostasis restoration.","journal":"Archives of pharmacal research"}],"companionDiagnostics":[],"genericManufacturers":4,"_genericFilersChecked":true,"genericManufacturerList":["Amphastar Pharms Inc","Cipla","Lupin Ltd","Mylan Labs Ltd"],"status":"approved","companyName":"Xeris","companyId":"xeris","modality":"Recombinant protein","firstApprovalDate":"1960","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1960-11-14T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1960-11-14T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1960-11-14T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1960-11-14T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1960-11-14T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1960-11-14T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-05-08T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"NDA201849"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2020-03-25T00:00:00.000Z","mah":"Eli Lilly Japan K.K.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-04-07T00:00:00.000Z","mah":"XERIS","brand_name_local":null,"application_number":"NDA212097"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-10-27T00:00:00.000Z","mah":"AMPHASTAR PHARMS INC","brand_name_local":null,"application_number":"NDA210134"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-12-28T00:00:00.000Z","mah":"AMPHASTAR PHARMS INC","brand_name_local":null,"application_number":"ANDA208086"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-09-15T00:00:00.000Z","mah":"CIPLA","brand_name_local":null,"application_number":"ANDA218813"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"81733.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":10,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:38:46.513095+00:00","fieldsConflicting":4,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}